Malignant pleural mesothelioma (MPM) is a rare malignancy characterized by very poor prognosis and lack of treatment options. Immunotherapy has rapidly emerged as an effective tool for MPM, particularly for tumors of non-epithelioid histology. At the same time, comprehensive genomic sequencing may open the way to new-generation targeted-drugs able to hit specific MPM molecular vulnerabilities. These innovations will possibly enrich, but also dramatically complicate, the elucidation of treatment algorithms. Multidisciplinary integration is urgently needed.
Vita, E., Stefani, A., Di Salvatore, M., Chiappetta, M., Lococo, F., Margaritora, S., Tortora, G., Bria, E., Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma, <<JOURNAL OF CLINICAL MEDICINE>>, 2021; 10 (11): N/A-N/A. [doi:10.3390/jcm10112290] [https://hdl.handle.net/10807/245995]
Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma
Vita, Emanuele;Stefani, Alessio;Di Salvatore, Mariantonietta;Lococo, Filippo;Margaritora, Stefano;Tortora, Giampaolo;Bria, Emilio
2021
Abstract
Malignant pleural mesothelioma (MPM) is a rare malignancy characterized by very poor prognosis and lack of treatment options. Immunotherapy has rapidly emerged as an effective tool for MPM, particularly for tumors of non-epithelioid histology. At the same time, comprehensive genomic sequencing may open the way to new-generation targeted-drugs able to hit specific MPM molecular vulnerabilities. These innovations will possibly enrich, but also dramatically complicate, the elucidation of treatment algorithms. Multidisciplinary integration is urgently needed.
| File | Dimensione | Formato | |
|---|---|---|---|
|
oncological front.pdf
accesso aperto
Tipologia file ?:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
241.33 kB
Formato
Adobe PDF
|
241.33 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
